Haw Par Past Earnings Performance
Past criteria checks 5/6
Haw Par has been growing earnings at an average annual rate of 5.4%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 1.8% per year. Haw Par's return on equity is 6.3%, and it has net margins of 98.1%.
Key information
5.4%
Earnings growth rate
5.4%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 1.8% |
Return on equity | 6.3% |
Net Margin | 98.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Haw Par Corporation Limited (SGX:H02) Might Not Be As Mispriced As It Looks
Sep 08Haw Par (SGX:H02) Has Announced A Dividend Of SGD0.20
Apr 25We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Haw Par Corporation Limited's (SGX:H02) CEO For Now
Apr 16Haw Par (SGX:H02) Has Announced A Dividend Of SGD0.20
Apr 02Haw Par (SGX:H02) Is Increasing Its Dividend To SGD0.20
Aug 14Haw Par (SGX:H02) Could Easily Take On More Debt
Jun 17Haw Par (SGX:H02) Has Announced A Dividend Of SGD0.15
Apr 04Haw Par (SGX:H02) Has A Rock Solid Balance Sheet
Oct 20Haw Par (SGX:H02) Will Pay A Dividend Of SGD0.15
Aug 12Haw Par (SGX:H02) Will Pay A Dividend Of S$0.15
Apr 28Haw Par (SGX:H02) Is Due To Pay A Dividend Of S$0.15
Apr 06Haw Par (SGX:H02) Has Affirmed Its Dividend Of S$0.15
Feb 27Haw Par (SGX:H02) Will Pay A Dividend Of S$0.15
Aug 23Is Haw Par Corporation Limited (SGX:H02) Popular Amongst Institutions?
Jan 24Should Haw Par Corporation Limited (SGX:H02) Be Part Of Your Dividend Portfolio?
Jan 03Haw Par Corporation Limited (SGX:H02) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Dec 13Shareholders Of Haw Par (SGX:H02) Must Be Happy With Their 50% Return
Nov 23Revenue & Expenses Breakdown
How Haw Par makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 239 | 234 | 69 | 0 |
31 Mar 24 | 236 | 225 | 70 | 0 |
31 Dec 23 | 232 | 217 | 71 | 0 |
30 Sep 23 | 215 | 196 | 65 | 0 |
30 Jun 23 | 198 | 175 | 59 | 0 |
31 Mar 23 | 190 | 162 | 57 | 0 |
31 Dec 22 | 182 | 148 | 55 | 0 |
30 Sep 22 | 176 | 141 | 57 | 0 |
30 Jun 22 | 171 | 134 | 58 | 0 |
31 Mar 22 | 156 | 122 | 54 | 0 |
31 Dec 21 | 141 | 110 | 49 | 0 |
30 Sep 21 | 119 | 96 | 41 | 0 |
30 Jun 21 | 96 | 82 | 34 | 0 |
31 Mar 21 | 104 | 101 | 34 | 0 |
31 Dec 20 | 111 | 120 | 35 | 0 |
30 Sep 20 | 140 | 118 | 40 | 0 |
30 Jun 20 | 181 | 161 | 49 | 0 |
31 Mar 20 | 211 | 206 | 52 | 0 |
31 Dec 19 | 244 | 182 | 61 | 0 |
30 Sep 19 | 253 | 190 | 63 | 0 |
30 Jun 19 | 257 | 190 | 64 | 0 |
31 Mar 19 | 251 | 182 | 66 | 0 |
31 Dec 18 | 238 | 179 | 62 | 0 |
30 Sep 18 | 233 | 173 | 63 | 0 |
30 Jun 18 | 226 | 156 | 64 | 0 |
31 Mar 18 | 222 | 125 | 66 | 0 |
31 Dec 17 | 223 | 122 | 68 | 0 |
30 Sep 17 | 222 | 128 | 63 | 0 |
30 Jun 17 | 218 | 130 | 58 | 0 |
31 Mar 17 | 210 | 128 | 56 | 0 |
31 Dec 16 | 202 | 125 | 53 | 0 |
30 Sep 16 | 189 | 124 | 55 | 0 |
30 Jun 16 | 187 | 116 | 56 | 0 |
31 Mar 16 | 186 | 184 | 57 | 0 |
31 Dec 15 | 179 | 183 | 53 | 0 |
30 Sep 15 | 176 | 183 | 53 | 0 |
30 Jun 15 | 167 | 174 | 51 | 0 |
31 Mar 15 | 161 | 120 | 48 | 0 |
31 Dec 14 | 154 | 119 | 47 | 0 |
30 Sep 14 | 153 | 124 | 47 | 0 |
30 Jun 14 | 152 | 120 | 47 | 0 |
31 Mar 14 | 147 | 112 | 44 | 0 |
31 Dec 13 | 141 | 108 | 43 | 0 |
30 Sep 13 | 144 | 119 | 46 | 0 |
Quality Earnings: H02 has high quality earnings.
Growing Profit Margin: H02's current net profit margins (98.1%) are higher than last year (88.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: H02's earnings have grown by 5.4% per year over the past 5 years.
Accelerating Growth: H02's earnings growth over the past year (33.8%) exceeds its 5-year average (5.4% per year).
Earnings vs Industry: H02 earnings growth over the past year (33.8%) exceeded the Pharmaceuticals industry 5.7%.
Return on Equity
High ROE: H02's Return on Equity (6.3%) is considered low.